drugset
drugset / Trial / NCT04757090

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

NCT04757090 ↗

Phase 2 Withdrawn Washington University School of Medicine Molecular Templates, Inc. · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This is an open-label, single center, pilot study to assess the feasibility of baseline 89Zr-trastuzumab PET/CT to predict response to treatment with monotherapy MT-5111

Timeline

Start
2021-12-31
Primary completion
2023-12-31
Completion
2023-12-31

Outcome

Outcome not reported

Stopped: “Insufficient staff”

Drugs

EvaluationDrugModalityDoseRoute
Subject 89Zr-trastuzumab Diagnostic / imaging agent — —

Indications

No indication recorded.